Sex Matters in How, When, and Where Melanomas Develop

Melanoma rates differ consistently between men and women in terms of the ages at which melanomas occur and the locations on the body where they occur. Over time, melanoma rates have increased in both men and women, but the trends differ by body site. A new study opens in new tab/window in the Journal of Investigative Dermatology opens in new tab/window, published by Elsevier, presents the findings from a large-scale, long-term melanoma data analysis investigating incidence trends by age, sex, and anatomic site.

Lead investigator David C. Whiteman, MBBS, PhD, Cancer Control Group, QIMR Berghofer Medical Research Institute, and Faculty of Medicine, The University of Queensland, Brisbane, Australia, explains, "There has been a general observation in numerous populations that melanomas appear to arise at different rates in men and women. We decided to investigate this observation rigorously and assess whether these differences have been constant through time or across generations by using large-scale data from population registries to investigate long-term melanoma trends in men and women.

The research team analyzed more than 40 years of melanoma data from Queensland, Australia, the USA, and Scotland. These three populations were chosen because historically they have had high (Queensland), moderate (USA), and low (Scotland) rates of melanoma. Over time, the rates of melanoma increased in all three populations, especially among women. In women in all populations, melanomas arise most commonly on the limbs, whereas in men, melanomas arise most commonly on the trunk and head and neck. In both sexes, there has been a steady increase in melanomas on the head and neck with increasing age.

Researchers found that in virtually all investigated populations, women experience higher rates of melanoma than men in early life (up to age ~45 years), but men develop melanomas at higher rates than women later in life (from ages ≥65 years). Furthermore, these sex-specific trends reflect complex patterns of incidence across body sites that vary consistently with age. Thus, in early life, women experience higher rates of lower limb melanomas than men, which persists into older ages. Also, on the upper limbs, women experience substantially higher rates than men from young ages until middle age (45-64 years), after which men experience higher rates. In contrast, on the head and neck and the trunk, melanomas occur at higher incidence in men than in women early in life. On all body sites, the rate at which melanoma incidence rises with age is much more rapid for men than for women.

The study confirms that men and women experience melanoma in different ways. While this is most likely driven by different patterns of sun exposure between men and women, there appear to be inherent differences in the ways in which melanomas develop at different body sites in women compared with men. Understanding the underlying biological differences could provide important clues about the etiology of this enigmatic cancer.

Dr. Whiteman concludes, “Invasive melanomas are potentially lethal cancers that are increasing rapidly in incidence. We need to understand how these cancers arise, and what drives their development, if we are to find better ways to prevent them. Studies like this one suggest that we may need to target our prevention efforts differently for men and women if we are to be effective in our attempts to control this cancer.”

Notes for editors

The article is “Does Sex Matter? Temporal Analyses of Melanoma Trends Among Men and Women Suggest Etiologic Heterogeneity,” by Catherine M. Olsen, Nirmala Pandeya, Adalberto Miranda-Filho, Philip S. Rosenberg, and David C. Whiteman (https://doi.org/10.1016/j.jid.2024.05.011 opens in new tab/window). It appears online in the Journal of Investigative Dermatology, published by Elsevier.

The article is openly available at https://www.jidonline.org/article/S0022-202X(24)01500-8/fulltext opens in new tab/window.

The full text of the article is also available to credentialed journalists upon request; contact Theresa Monturano at +1 215 239 3711 or [email protected] opens in new tab/window. Journalists wishing to interview the authors should contact Bridget Smith, Media, Communications and Government Relations Manager, QIMR Berghofer, at [email protected] opens in new tab/window.

The authors would like to thank the Cancer Alliance Queensland who manage the Queensland Cancer Register and Lesley Bhatti from the Scottish Cancer Registry for their assistance in providing the data for these analyses. This work was supported in part by the National Health and Medical Research Council of Australia (grant number 1185416) and research grants from the National Health and Medical Research Council of Australia (1155413, 2026567).

About the Journal of Investigative Dermatology

The Journal of Investigative Dermatology opens in new tab/window (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.org opens in new tab/window

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.